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edicine is experiencing an unprecedented focus on quan-
ifying and improving health care quality. The American
ollege of Cardiology (ACC) and the American Heart
ssociation (AHA) have developed a multi-faceted strategy
o facilitate the process of improving clinical care. The
nitial phase of this effort was to create clinical practice
uidelines that carefully review and synthesize available
vidence to better guide patient care. Such guidelines are
ritten in a spirit of suggesting diagnostic or therapeutic
nterventions for patients in most circumstances. Accord-
ngly, significant judgment by clinicians is required to adapt
hese guidelines to the care of individual patients, and these
uidelines can be generated with varying degrees of confi-
ence based upon available evidence.
Occasionally, the evidence supporting a particular structural
spect or process of care is so strong that failure to perform
uch actions reduces the likelihood that optimal patient out-
omes will occur. Creating a mechanism for quantifying these
pportunities to improve the outcomes of care is an important
nd pressing challenge. In the next phase of its quality
mprovement efforts, the ACC and the AHA created the
CC/AHA Task Force on Performance Measures in February
000 to spearhead the development of performance measures that
llow the quality of cardiovascular care to be assessed and im-
roved. Three nominees from each organization were charged
ith the task of assembling teams of clinical and methodolog-
cal experts, both from within the sponsoring organizations and
rom other organizations dedicated to the care of patients
overed by the performance measurement set. These writing
ommittees were given careful guidance with respect to the
ecessary attributes of good performance measures and the
rocess of identifying, constructing, and refining these mea-
ures so that they can accurately achieve their desired goals (1).
The role of performance measurement writing commit-iterature; this is undertaken by ACC/AHA guidelines
ommittees. However, performance measurement writing
ommittees work collaboratively with guidelines committees
o that the guideline recommendations are written with a
egree of specificity that supports performance measure-
ent and so that new knowledge can be rapidly incorpo-
ated into performance measurement. Development of
CC/AHA guidelines includes a detailed review of and
anking of the evidence available for the diagnosis and
reatment of specific disease areas. Published guideline
ecommendations employ the ACC/AHA classification
ystem I, IIa, IIb, and III (Table 1).
So as not to duplicate performance measure development
fforts, writing committees were also instructed to evaluate
xisting nationally recognized performance measures using
he ACC/AHA “attributes of good performance measures.”
he measure specifications were adopted for those perfor-
ance measures that meet these criteria. Such measures
ave established validity, reliability, and feasibility and will
orm the foundation of the ACC/AHA measurement sets.
urthermore, writing committees are encouraged to identify
dditional performance measures that correspond to those
ey areas of quality proven to improve patient outcomes.
The ACC/AHA Performance Measurement Sets are
o be applied in the inpatient and/or outpatient setting
epending upon the topic. Although inpatient measures
ave traditionally been captured by retrospective data
ollection, the increased use of electronic medical records
llows for prospective collection in the inpatient and
utpatient settings. Prospective data collection is itself a
ontinuous quality improvement process. The perfor-
ance measures quantify explicit actions performed in
arefully specified patients for whom adherence should be
dvocated in all but the most unusual circumstances. In
ddition, the measures are constructed with the intent to
acilitate both retrospective and prospective data collec-
ion using explicit administrative and/or easily docu-
ented clinical criteria. Furthermore, the data elements
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33equired to construct the performance measures are
dentified and linked to existing ACC/AHA Clinical
ata Standards to encourage the standardization of
ardiovascular measurement.
While the focus of the performance measures writing
ommittees is to develop measures for internal quality
mprovement, it is appreciated that other organizations may
se these measures for external reporting of provider per-
ormance. Therefore, it is within the scope of the writing
ommittee’s task to comment on the strengths and limita-
ions of externally reporting potential performance mea-
ures. Specifically, this was done in the “Challenges to
mplementation” sections in each of the performance mea-
ures when appropriate (see Appendixes A and B).
All the measures contained in this set have limitations
nd challenges to implementation that could result in
nintended consequences when used for accountability pur-
oses. The implementation of these measures for purposes
ther than quality improvement (QI) require field testing to
ddress issues related to, but not limited to, sample size,
easonable frequency of use for an intervention, compara-
ility, and audit requirements. The way in which these
ssues are addressed will be highly dependent on the type of
able 1. Applying Classification of Recommendations and Leve
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ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may be
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested ph
entences that express a complete thought, such that a recommendation, even if separated and
ould still convey the full intent of the recommendation. It is hoped that this will increase readccountability system developed, including data collection pethod, assignment of patients to physicians for measure-
ent purposes, baseline measure setting, incentive system,
nd public reporting method among others. The ACC/
HA encourages those interested in working on implemen-
ation of these measures for purposes beyond QI to work
ith the ACC/AHA to understand these complex issues in
ilot testing projects that can measure the impact of any
imitations and provide guidance on possible refinements of
he measures that would make them more suitable for
dditional purposes.
In the process of facilitating the measurement of
ardiovascular health care quality, the ACC/AHA Per-
ormance Measurement Sets can serve as a vehicle for
ore rapidly translating the strongest clinical evidence
nto practice. These documents are intended to provide
ractitioners with “tools” for measuring the quality of
are and for identifying opportunities to improve. Be-
ause the target audience and unit of analysis for these
easures is the practitioner, they were constructed from
he provider’s perspective and were not intended to
haracterize “good” or “bad” practice but to be part of a
ystem with which to assess and improve health care
uality. It is our hope that an application of these
vidence†
T EFFECT” 
with focused 
LE to perform 
ter treatment 
Class IIb 
  
Benefit ≥ Risk 
Additional studies with broad 
objectives needed; Additional 
registry data would be helpful
Procedure/Treatment
MAY BE CONSIDERED
 in favor of 
cedure being 
evidence from 
ized trials or 
• Recommendation’s 
usefulness/efficacy less well 
established
• Greater conflicting evidence 
from multiple randomized trials 
or meta-analyses 
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Sufficient evidence from 
multiple randomized trials or 
meta-analyses
 in favor of 
cedure being 
evidence from 
d trial or non-
ies 
• Recommendation’s 
usefulness/efficacy less well 
established
• Greater conflicting evidence 
from single randomized trial or 
non-randomized studies 
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Limited evidence from single 
randomized trial or non-
randomized studies 
 in favor of 
cedure being 
pert opinion, 
tandard-of-
• Recommendation’s 
usefulness/efficacy less well 
established
• Only diverging expert opinion, 
case studies, or standard-of-care
• Recommendation that 
procedure or treatment not 
useful/effective and may be 
harmful
• Only expert opinion, case 
studies, or standard-of-care 
Class III 
  
Risk ≥ Benefit 
No additional studies needed 
 
Procedure/Treatment should 
NOT be performed/administered 
SINCE IT IS NOT HELPFUL 
AND MAY BE HARMFUL 
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
clear clinical consensus that a particular test or therapy is useful or effective.
o use when writing recommendations. All guideline recommendations have been written in full
nted apart from the rest of the document (including headings above sets of recommendations),
prehension of the guidelines and will allow queries at the individual recommendation level.l of E
MEN
isk 
tudies 
eeded 
ONAB
dminis
dation
 or pro
ctive
licting 
andom
yses
dation
 or pro
ective 
licting 
domize
ed stud
dation
 or pro
ective 
ging ex
es, or s
lations
at the r
a very
rases terformance measures within a system of QI will provide
a
c
I
O
p
s
w
i
i
v
(
h
A
R
o
R
s
T
p
s
2
p
i
c
i
(
s
h
p
p
a
m
p
i
c
g
B
w
c
t
A
S
T
m
s
•
•
•
•
r
C
b
c
i
u
r
B
T
A
1403JACC Vol. 50, No. 14, 2007 Thomas et al.
October 2, 2007:1400–33 AACVPR/ACC/AHA Performance Measuresmechanism through which the quality of medical care
an be measured and improved.
Robert O. Bonow, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Performance Measures
. Introduction
ver the past 4 decades, cardiac rehabilitation/secondary
revention (CR) services have become recognized as a
ignificant component in the continuum of care for persons
ith cardiovascular disease (CVD). The role of CR services
n the comprehensive secondary prevention of CVD events
s well documented (2–12) and has been promoted by
arious health care organizations and position statements
4,12–18). However, performance measures for CR services
ave not been published to date.
To formalize performance measures for CR services, the
merican Association of Cardiovascular and Pulmonary
ehabilitation (AACVPR)/American College of Cardiol-
gy (ACC)/American Heart Association (AHA) Cardiac
ehabilitation/Secondary Prevention Performance Mea-
ures Writing Committee was convened in November 2005.
he Writing Committee was given the charge of developing
erformance measures that cover 2 specific aspects of CR
ervices: 1) referral of eligible patients to a CR program and
) delivery of CR services through multidisciplinary CR
rograms.
The ultimate purpose of these performance measure sets
s to help improve the delivery of CR in order to reduce
ardiovascular mortality and morbidity and optimize health
n persons with CVD, including acute myocardial infarction
MI) or status-post coronary artery bypass graft (CABG)
urgery, percutaneous coronary intervention (PCI), and
eart transplant or heart valve surgery. Using the previously
ublished methodology of the ACC and the AHA (1,19),
erformance measures for the referral of eligible patients to
CR program, and the delivery of CR services through
ultidisciplinary CR programs were developed, focusing on
rocesses of care that have been documented to help
mprove patient outcomes (using the ACC/AHA system for
lassification of recommendations and level of evidence for
uidelines and clinical recommendations shown in Table 1).
oth inpatient and outpatient settings of cardiovascular care
ere considered, resulting in performance measures being
reated for 3 specific settings: 1) hospitals, 2) office prac-
ices, and 3) CR programs.
. Rationale for Cardiac Rehabilitation/
econdary Prevention Performance Measures
he rationale for developing and implementing perfor-
ance measure sets for referral to and delivery of CR
ervices is based on several key factors:
There has been growing scientific evidence over the past
3 decades of the benefits of CR services for persons with
CVD (2,17,20). Evidence suggests that the benefits of PCR services are as significant in recent years as they were
in the pre-thrombolytic era (9,21). Because of this
mounting evidence, a number of health care organiza-
tions have endorsed the use of CR services in persons
with CVD by including provisions for CR in their
practice guidelines and practice management position
papers (4,12,13,18,21,22,23).
Despite the known benefits of CR and despite the
widespread endorsement of its use, CR is vastly under-
utilized, with less than 30% of eligible patients partici-
pating in a CR program after a CVD event (24–26).
Reasons for this gap in CR participation are numerous,
but the most critical and potentially most correctable
reasons revolve around obstacles in the initial referral of
patients to CR programs. These obstacles can be reduced
through the systematic adoption of standing orders and
other similar tools for CR referral for appropriate hospi-
talized patients (27). Furthermore, physician account-
ability associated with the use of these performance
measures may lead to new and novel approaches to
improve referral rates and improve the outcome of
patients with CVD.
Standards for CR programs have been previously pub-
lished (28), and systems for CR program certification
exist, such as the certification process offered through the
AACVPR for CR programs that meet their standards of
practice. Unfortunately, since such certification is not
required for CR program operation or for reimbursement
purposes, CR program certification is obtained by a
relatively small portion of CR programs in the United
States. As of October 2006, only 973 (37%) out of an
estimated 2,621 CR programs operating in the United
States have AACVPR certification (29) (personal com-
munication, A. Lynn, October 31, 2006).
Recommendations for CR referral and participation are
included in many practice guidelines and position papers
regarding the care of persons with CVD, but to date, no
groups have included referral to CR services in their
CVD-related performance measure sets. Likewise, there
are no currently available performance measure sets that
include measures for the delivery of CR services by
outpatient CR programs.
Clearly there is a need and also a prime opportunity to
educe the gap in delivery of CR services to persons with
VD. Such an improvement in CR delivery will require
etter approaches in the referral to, enrollment in, and
ompletion of programs in CR. It is anticipated that the
mplementation of CR performance measure sets will stim-
late changes in the clinical practice of preventive and
ehabilitative care for persons with CVD.
. Writing Committee Structure and Members
o formalize performance measures for CR services, the
ACVPR/ACC/AHA Cardiac Rehabilitation/Secondary
revention Performance Measures Writing Committee was
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33onvened in November 2005. The Writing Committee was
omposed of nominated representatives from the AACVPR,
he ACC, and the AHA, including past and current
epresentatives of the ACC Task Force on Performance
easures, past and current presidents of AACVPR, and
linicians with expertise in general clinical cardiology, heart
ailure, CVD, and CR. An initial committee meeting was
eld in Kansas City, Missouri, on January 23 and 24, 2006.
ommittee meetings were otherwise held by teleconference,
enerally at weekly intervals.
. Relationships With Industry
ommittee members volunteered their time to participate
n the Writing Committee and acknowledged any potential
onflicts of interest (Appendix D). The cost of the initial
ommittee meeting in January 2006 and the cost of confer-
nce calls were supported by the AACVPR, the ACC, and
he AHA. No commercial support was provided for any
spect of the Committee’s work.
. Review and Endorsement
public comment period was held for this document from
ecember 11, 2006, until January 11, 2007. Reviewers were
sked to provide comments on the document on the basis of
he rating form and guide shown in Appendix C. Reviewer
omments were considered and incorporated into a revised
ersion of the document. Review and final approval of the final
ersion of the paper was obtained through the governing
odies from the AACVPR, the ACC, and the AHA. En-
orsement of the final paper was sought from key partnering
rganizations.
I. Methodology
. Definition of Cardiac Rehabilitation/
econdary Prevention
ver the past decade, various CR program delivery para-
igms have evolved from the traditional definition where
rograms operate within a CR center and patients attend
essions in person. Some examples of these programs
nclude those programs that have staff members provide CR
ervices to patients through novel methods such as those
hat are home-, telephone-, or Internet-based.
The definition for CR in general use today is based on a
odification from the original World Health Organization
964 definition of CR (30). This definition reinforced the
bservation that CR is an integral component in the overall
anagement of patients with CVD, that the patient plays a
ignificant role in the successful outcome of CR, and that
R is an important source of services aimed at the second-
ry prevention of CVD events (2,4,12).
Building on this original definition, a number of other
omplementary definitions of CR have been promulgated by
arious organizations including the U.S. Public Health
ervice, the AHA, the AACVPR, and the Canadian
ssociation of Cardiac Rehabilitation (4,18). These up- fated definitions emphasize the integral role of CR in the
econdary prevention of CVD.
The definition used by the U.S. Public Health Service
nd by the Cardiac Rehabilitation/Secondary Prevention
erformance Measures Writing Committee is as follows:
“Cardiac rehabilitation services are comprehensive, long-term
programs involving medical evaluation, prescribed exercise,
cardiac risk factor modification, education, and counselling.
These programs are designed to limit the physiologic and
psychological effects of cardiac illness, reduce the risk for
sudden death or re-infarction, control cardiac symptoms,
stabilize or reverse the atherosclerotic process, and enhance the
psychosocial and vocational status of selected patients” (4).
ardiac rehabilitation/secondary prevention programs are
enerally divided into 3 main phases:
. Inpatient CR (also known as Phase 1 CR): a program
that delivers preventive and rehabilitative services to
hospitalized patients following an index CVD event,
such as an MI/acute coronary syndrome;
. Early outpatient CR (also known as Phase 2 CR): a
program that delivers preventive and rehabilitative services
to patients in the outpatient setting early after a CVD event,
generally within the first 3 to 6 months after the event but
continuing for as much as 1 year after the event;
. Long-term outpatient CR (also known as Phase 3 or
Phase 4 CR): a program that provides longer term
delivery of preventive and rehabilitative services for
patients in the outpatient setting.
The main focus of this position paper is on the referral to
nd delivery of early outpatient CR services principally
ecause it is the component of CR that has been most
idely documented to help reduce the risk of CVD mor-
ality among its participants.
. Definition of Appropriate Patients for Cardiac
ehabilitation/Secondary Prevention
atients who are considered eligible for CR include those
ho have experienced 1 or more of the following conditions
s a primary diagnosis sometime within the previous year:
MI/acute coronary syndrome*
CABG*
PCI*
Stable angina*
Heart valve surgical repair or replacement
Heart or heart/lung transplantation
The thrust of this document is focused on the manage-
ent of persons with coronary artery disease-related condi-
ions (noted in the list above with an *), but CR services are
onsidered appropriate and beneficial for persons: 1) after
eart valve surgical repair or replacement, and 2) after heart
r heart/lung transplantation (as previously listed) (31–34).
urthermore, growing evidence from published studies
upports a benefit of CR for persons with chronic heart
ailure or peripheral arterial disease (35,36). However,
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October 2, 2007:1400–33 AACVPR/ACC/AHA Performance Measuresormal recommendations by health care organizations to
pprove and/or cover CR services in these patient popula-
ions will depend upon policy decision-makers and, partic-
larly in the case of chronic heart failure, the results of
ngoing research studies.
Persons who are potentially eligible for CR may, in fact,
ave barriers that limit their participation in CR. Such
arriers include those that are patient-oriented (e.g., patient
efusal), others that are provider-oriented (e.g., provider
eems the patient ineligible for CR due to a high-risk
edical condition and/or an absolute contraindication to
xercise), and still others that are related to the health care
ystem and/or societal barriers (e.g., lack of a CR program,
ack of insurance coverage, etc.) (17). Patients with such
arriers may be excluded from the number of patients who
re considered to be eligible for CR referral (Appendix A,
nder “Numerator” criteria for assessing the percentage of
ligible patients who have been referred to a CR program).
t should be noted, however, that even though some persons
ay have significant patient- or provider-oriented barriers
o CR referral, nearly all patients with CVD can benefit
rom at least some components of a comprehensive, second-
ry prevention CR program.
. Overview of Performance Measures Created
oth structure-based and process-based performance mea-
ures are included in the Cardiac Rehabilitation/Secondary
revention Performance Measurement Sets. While impor-
ant and related, specific measures focused on clinical
utcomes are not included. The performance measures that
re included are designed to help health care groups identify
otentially correctable and actionable “upstream” sources of
uboptimal clinical care, such as structure- and process-
ased gaps in CR services. Details for the dimensions of care
ncluded in the Cardiac Rehabilitation/Secondary Preven-
ion Performance Measurement Sets are outlined as follows:
. Structure-based measures quantify the infrastructure
from which CR is provided and are based on the
provision of appropriate personnel and equipment to
satisfy high-quality standards of care for CR services. For
example, a structure-based performance measure for a
CR program is one that specifies that a CR program has
appropriate personnel and equipment to provide rapid
care in medical emergencies that may occur during CR
program sessions.
. Process-based measures quantify specific aspects of care
and are designed to capture all relevant dimensions of
CR care. For example, a process-based performance
measure for a CR program is one that specifies that all
patients in a CR program undergo comprehensive, stan-
dardized assessment of their cardiovascular risk factors
upon entry to the CR program.
It should also be noted that the Cardiac Rehabilitation/
econdary Prevention Performance Measurement Sets have
een designed for 3 different geographical settings of care: c) the hospital, 2) the physician office, and 3) the CR
rogram settings. Staff members within each of these areas
ho help provide care to persons with CVD are held
ccountable for the various aspects of CR services (referral
o, enrollment in, and delivery of CR services).
. Literature Review and Evidence Base
here is substantial evidence to conclude that CR is reasonable
nd necessary following MI, CABG surgery, stable angina,
eart valve repair or replacement, PCI, and heart or heart/lung
ransplant (12). Outpatient, medically supervised CR, as de-
cribed by the U.S. Public Health Service, is a comprehensive,
ong-term intervention including medical evaluation, pre-
cribed exercise, cardiac risk-factor modification, education,
nd counseling typically initiated 1 to 3 weeks after hospital
ischarge and typically including electrocardiographic moni-
oring of patients (see Section II.A.) (4).
Meta-analyses and systematic reviews (2,3,5–11) pro-
ide and summarize the extensive evidence that has been
enerated from published randomized clinical trials dem-
nstrating that exercise-based CR services are beneficial
or patients with established CVD. These benefits in-
lude improved processes of care and risk-factor profiles
hat are closely linked to subsequent mortality and
orbidity. Pooled data from randomized clinical trials of
R demonstrate a mortality benefit of approximately
0% to 25% (2,3,5–11) and a trend towards reduction in
onfatal recurrent MI over a median follow-up of 12
onths (10).
. Definition and Selection of Measures
he Cardiac Rehabilitation/Secondary Prevention Perfor-
ance Measure Writing Committee initially identified 39
actors from various practice guidelines and other reports that
ere considered potential performance measures for the Car-
iac Rehabilitation/Secondary Prevention Performance Mea-
urement Sets (see Table 1 for standard guidelines that were
sed to rate the classification of recommendations and level of
vidence for assessing these factors). The group evaluated these
9 factors according to guidelines established by the ACC/
HA Task Force on Performance Measures (1). Those
easures that were deemed to be most evidence-based, inter-
retable, actionable, clinically meaningful, valid, reliable, and
easible were included in the final performance measurement
ets. Once these measures were identified, the Writing Com-
ittee then discussed and refined, over a series of months, the
efinition, content, and other details of each of the selected
easures.
While most performance measures are designed for a
pecific condition and phase of a particular disease, CR referral
s applicable and appropriate for a number of different condi-
ions and phases of CVD. Accordingly, the Writing Commit-
ee created 2 sets of performance measures, one related to the
ppropriate referral of patients to a CR program and another
et related to optimal performance of a CR program itself. In
reating the first set, the Writing Committee sought to create
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33measure that would be appropriate for insertion into other
erformance measurement sets for which CR referral would be
ppropriate (e.g., performance measurement sets for care of
atients following MI, PCI, or CABG). Figure 1 outlines the
verall organization of these 2 types of measures and their
ntended applications.
II. Measures Related to
arly Outpatient CR Referral
he performance measures that are related to the referral of
ppropriate patients to an early outpatient CR program are
escribed in the next section.
. Populations, Care Period, and
esponsible Parties
atients who are appropriate for referral to an early
utpatient CR program include those patients who, in
he previous 12 months, have had any of the diagnoses
isted in Section II.B. The CR services are generally most
eneficial when delivered soon after the index hospital-
zation. However, there are often clinical, social, and
ogistical reasons which delay enrollment in CR. For this
eason, many third-party payers allow CR services to
egin up to 6 to 12 months following a cardiac event.
ecause patients can be referred to CR at varying times
ollowing a CVD event, parties responsible for the
eferral of patients to CR include hospitals and health
are systems as well as physician practices and other
ealth care settings with primary responsibility for the
igure 1. Intended Application of the Cardiac Rehabilitation/
econdary Prevention Performance Measurement Sets A and B
iagram shows the relationship between the Cardiac Rehabilitation/Secondary
revention Performance Measurement Sets A and B and the patient sub-groups
or which the Performance Measurement Sets apply. CABG  coronary artery
ypass grafting; MI  myocardial infarction; PCI  percutaneous coronary
ntervention.are of patients after a CVD event. f. Brief Summary of the Measures
he Cardiac Rehabilitation/Secondary Prevention Perfor-
ance Measurement Set A (Appendix A) is based on 2
riteria for the appropriate referral of patients to an early
utpatient CR program:
. All hospitalized patients with a qualifying CVD event
are referred to an early outpatient CR program prior to
hospital discharge; and
. All outpatients with a qualifying diagnosis within the
past year who have not already participated in an early
outpatient CR program are referred to an early outpa-
tient CR program by their health care provider.
It should be noted that the health care system and its
roviders who care for patients during and/or after CVD
vents are accountable for these performance measures.
hysicians or other health care providers who see patients
ith CVD but who do not have a primary role in managing
heir CVD are not accountable for meeting these criteria.
or example, an ophthalmologist who is performing an
nnual retinal exam on a diabetic patient in the year after
heir MI would not be responsible for referring the patient
o a CR program. Additional details regarding this perfor-
ance measurement set are included in Appendix A.
. Data Collection Instruments
xamples of tools that may be of help in applying the
ardiac Rehabilitation/Secondary Prevention Perfor-
ance Measurement Set A (Appendix A) into practice
re included in Figures 2 and 3. In Figure 2, an example
s shown of a standardized CR referral tool that health
are systems could potentially use in the inpatient setting,
hereas Figure 3 shows an example of a potential CR
eferral tool for outpatient practice settings. Figure 4
hows an example of a performance measure tracking tool
hat can be used by health care systems following an MI,
ith the performance measure of CR referral included in
he performance measurement tool. These tools are given
s examples and not as endorsed instruments. Health care
ystems and providers are encouraged to develop and
mplement systematic tools that are most appropriate and
ost effective for their particular setting and patient
opulation groups.
. Inclusion in Other Performance
easurement Sets
he Cardiac Rehabilitation/Secondary Prevention Perfor-
ance Measurement Set A (Appendix A) is designed to be
ncluded in (i.e., “plugged into”) other related performance
easurement sets for which referral to a CR program would be
onsidered an appropriate component of high-quality care
e.g., can be “plugged into” the performance measurement set
or management of patients with myocardial infarction).
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arly Outpatient CR Programs
he second set of performance measures included in the
ardiac Rehabilitation/Secondary Prevention Performance
easurement Sets—Performance Measurement Set B (Ap-
igure 2. Example of a Referral Tool for an Inpatient to an Outpati
ool to be considered for use with the Cardiac Rehabilitation/Secondary Prevention
alz KA, et al. Mayo Clinic’s Order Set for Provider Referral to Outpatient Cardiac Re
ochester, MN (37). CR  cardiac rehabilitation/secondary prevention program.endix B)—relates to the optimal structure and processes of iare for CR programs themselves and is described in the next
ection.
. Populations, Care Period, and
esponsible Parties
atients who are appropriate for entry into a CR program
R Program
ance Measurement Set A. Adapted with permission from Zarling KK, Schad SP,
ation (Phase II). Mayo Foundation for Medical Education and Research, 2005.ent C
Performnclude persons 18 years of age or older who, during the
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33revious year, have had 1 or more of the qualifying diag-
oses listed in Section II.B. Patients who are considered
neligible for CR services, by patient-oriented or provider-
riented criteria (see Section II.B.), may still be appropriate
andidates for enrollment in modified CR programs that
dapt their services to a given patient’s limitations, geo-
igure 3. Example of Referral Tool for an Outpatient to an Outpati
ample tool for referring outpatients to an early outpatient/secondary prevention pro
erformance Measurement Set A. Adapted with permission from Zarling KK, Schad S
ehabilitation (Phase II). Mayo Foundation for Medical Education and Research, 200raphic or otherwise. The period of care for early outpatient CR typically begins 1 to 3 weeks after the index CVD event
nd lasts up to 3 to 6 months.
The unit of analysis for the Cardiac Rehabilitation/
econdary Prevention Performance Measurement Set B is
he health care system’s CR program(s). Therefore, the
esponsible parties for the performance of early outpatient
R Program
to be considered for use with the Cardiac Rehabilitation/Secondary Prevention
lz KA, et al. Mayo Clinic’s Order Set for Provider Referral to Outpatient Cardiac
hester, MN (37). CR  cardiac rehabilitation/secondary prevention.ent C
gram,R services include members of the CR program staff—the
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October 2, 2007:1400–33 AACVPR/ACC/AHA Performance Measuresigure 4. Example of a Tracking Tool for Assessing the Provision of Appropriate Prevention Therapies,
ncluding Referral to a CR Program, for Patients Hospitalized With a CAD Event
ata collection tool to be considered for use with the Cardiac Rehabilitation/Secondary Prevention Performance Measurement Set A (adapted from American Heart Associa-
ion’s Get With The Guidelines) (38). ACE  angiotensin-converting enzyme; CAD  coronary artery disease; CR  cardiac rehabilitation/secondary prevention; MI  myocar-
ial infarction; w/o  without.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33edical director, nurses, exercise specialists, cardiovascular
dministrators, and other members of the CR team.
. Brief Summary of the Outpatient
R Program Measurement Set
he Cardiac Rehabilitation/Secondary Prevention Perfor-
ance Measurement Set B for the delivery of CR services
ncludes those measures that were considered by the Writ-
ng Committee to have the highest level of evidence and
onsensus support among the Committee members.
The measures selected include both structure- and
rocess-based measures that assess for the use of the
ollowing policies and procedures by CR programs:
tructural measures (Appendix B: Performance Measure
-1)
A physician medical director is responsible for the
program
An emergency response team with appropriate emer-
gency equipment and trained staff is available during
patient care hours
rocess measures (Appendix B: Performance Measures B-2,
-3, and B-4)
Assessment and documentation of each patient’s risk for
adverse events during exercise
A process to assess patients for intercurrent changes in
symptoms
Individualized assessment and evaluation of modifiable
CVD risk factors
Development of individualized risk reduction interven-
tions for identified conditions and coordination of care
with other health care providers
Evidence of a plan to monitor response and document
program effectiveness through ongoing analysis of aggre-
gate data. This includes:
X A plan to assess completion of the prescribed course
of CR
X A standardized plan to reassess patient outcomes at
the completion of CR
Methodology to document program effectiveness and
initiate quality improvement strategies
ppendix B provides the detailed specifications for each
utpatient performance measure.
. Data Collection Instruments
he Cardiac Rehabilitation/Secondary Prevention Perfor-
ance Measurement Set B is intended to be used prospec-
ively to review a program’s internal procedures with the
ltimate goal of enhancing the quality improvement pro-
ess. To aid in data compilation, ideally collected prospec-
ively, a data collection tool or flow sheet is recommended.
n example of such a collection tool is shown in Table 2. realth care systems and practices are encouraged to develop
nd/or use a tool that conforms to local practice patterns and
tandards.
. Discussion
he aim of the Cardiac Rehabilitation/Secondary Preven-
ion Performance Measures Writing Committee was to
ddress 2 important, persistent gaps in the quality of care for
atients with CVD: namely, inadequate referral rates to CR
rograms and the need for minimum performance standards
or such CR programs. Currently, a minority of patients
eceive CR services and secondary prevention services due,
n general, to a number of patient-, provider-, and health
are system-related barriers. The Writing Committee de-
igned performance measurement sets that hold health care
roviders, CR program staff members, and leaders of health
are systems accountable for the ultimate goal of linking
ligible patients to the appropriate CR services following a
ualifying CVD event.
The Writing Committee focused its attention on two
eneral performance measurement sets: 1) referral of eligible
atients to an outpatient CR program, and 2) delivery of
ppropriate CR services by CR programs. The first perfor-
ance measure is designed to be used as a plug-in compo-
ent to other performance measurement sets for which CR
eferral is deemed appropriate (e.g., post-MI, post-CABG,
ost-PCI). The second performance measurement set is
esigned to clarify structure- and process-based perfor-
ance measures that serve as a standard for CR programs as
hey work to continually improve the quality of care pro-
ided to their patients with CVD and thereby optimize their
atients’ health-related outcomes.
The Writing Committee did not include performance
easures for all patient groups that may benefit from CR
ervices, but focused on those groups of patients with the
ost current scientific evidence and other supporting evi-
ence for benefits from CR. Other patient groups, including
hose patients who have undergone heart valve surgery or
ho have received heart or heart/lung transplantation, are
lso appropriate for CR referral. In addition, there is
rowing evidence for the benefits of CR in persons with
ther cardiovascular conditions, including heart failure and
eripheral vascular disease. As more evidence becomes
vailable for the benefits of CR in these patient groups, they
ill be included in future iterations of the Cardiac Reha-
ilitation/Secondary Prevention Performance Measurement
ets.
To be effective, the recommendations of the Writing
ommittee will need to be adapted, adopted, and imple-
ented by health care systems, health care providers, health
nsurance carriers, chronic disease management organiza-
ions, and other groups in the health care field that have
esponsibility for the delivery of care to persons with CVD.
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American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Cardiology, and American Heart Association Cardiac
Rehabilitation/Secondary Prevention Program Performance Measurement Set Data Collection Flow Sheet (ideally collected prospectively)
atient Name or Code: Birth Date:
ender:□M □F Date of event(s):
iagnosis:□MI □CABG □Angina □Valve repair or replacement □PCI □Transplantation □CHF
ace/Ethnicity:□African American □Asian American □Native American □Non-White Hispanic □White □Other
isk Category□Low □Moderate □High
Target Goal Initial Assessment
Intervention Plan and
Communication
Reassessment Prior
to Completion of
Program
Changes in Intervention Plan
and Communication
ate
obacco Use Complete cessation of
tobacco use
□ Never
□ Recent (quit less 6
months ago)
□ Current
Complete only if current or
recent tobacco use
□ Individual education and
counseling
or
□ Referral to a tobacco
cessation program
and
□ Health care provider notified
□ Abstaining
□ Smoking
Complete only if still smoking
□ Individual education and
counseling
or
□ Referral to a tobacco
cessation program
and
□ Health care provider notified
lood Pressure
ontrol
140/90 mm Hg
or130/80 mm Hg if
patient has diabetes
or chronic kidney
disease
□ Patient with
diagnosis of treated
or untreated
hypertension
□ Not hypertensive
Complete only if patient has a
diagnosis of hypertension:
Education completed:
□ Target BP goal
□ Medication compliance
□ Lifestyle modification
□ Intermittent
monitoring of BP
during CR
□ Policy in place concerning
communication with health
care providers, including
thresholds for communication
ipid Control For CVD and CVD
equivalents:
LDL-C100 mg/dL if
triglycerides are 200
mg/dL, non–HDL-C
should be130 mg/dL
□ Optimal control
□ Suboptimal control
Applies to all patients with
CVD:
Education completed:
□ Target lipid goals
□ Medication compliance
□ Lifestyle modification
Complete only if
suboptimal control
on initial
assessment:
□ Patient
encouraged to
contact health care
provider about
reassessment of
lipid control
□ Policy is in place to
communicate with health care
providers as needed
hysical
ctivity Habits
30 min, minimum
5 d per week
□ Optimal habits
□ Suboptimal habits
□ Education completed
concerning optimal physical
activity habits
□ Optimal habits Complete only if habits remain
suboptimal
Complete only if habits are
suboptimal
□ Suboptimal
habits
□ An intervention plan is
developed with the patient
□ Intervention plan developed
with the patient
□ Health care provider notified
eight
anagement
Body mass index:
18.5 to 24.9 kg/m2
and
Waist circumference:
men40 inches
women35 inches
□ At target
□ Above target
Applies to all patients
□ Education completed
concerning target goals, diet,
behavior change, regular
physical activity
or
□ Referral to a weight
management program
and
□ Health care provider notified
if above target
□ At target
□ Above target
Complete only if remains above
target
□ Additional education
completed for target goals,
diet, behavior change, exercise
or
□ Referral to a weight
management program
and
□ Health care provider notified
Continued on next page
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Target Goal Initial Assessment
Intervention Plan and
Communication
Reassessment Prior
to Completion of
Program
Changes in Intervention Plan
and Communication
resence or
bsence of
M or IFG
fasting blood
lucose 110–
25
g/dL)
HbA1C7% □ Diagnosis of DM or
IFG present
□ Diagnosis of DM or
IFG absent
Complete only if diabetes
mellitus is present:
□ Documentation that patient
has attended skill training and
medical nutrition therapy
session
or
□ Referral to skill training and
medical nutrition therapy
session
or
□ Intervention plan
recommended which includes:
target goals for HbA1C, medical
nutrition counseling, and skill
training
Complete only if IFG is present:
□ Education is completed
concerning the importance of
weight management and
physical activity
Complete only if
diabetes mellitus or
IFG is present:
□ Attendance at
appropriate
education or skill
training session
□ A policy is in place
concerning communication
with appropriate health care
professionals including
thresholds for notification
resence or
bsence of
epression
Assessment of
presence or absence
of depression using a
valid and reliable
screening tool
□ Patient screened
for depression
□ Patient not
screened for
depression
Complete only if screening tool
indicates possible depression:
□ Results discussed with
patient
and
□ Health care provider notified
□ Patient re-
screened for
depression
□ Patient not re-
screened for
depression
Complete only if screening tool
indicates possible depression:
□ Results discussed with
patient
and
□ Health care provider notified
xercise
apacity
Assessment of
symptom-limited
exercise tolerance and
development of an
individualized exercise
prescription
□ Assessment and
exercise prescription
completed
□ Assessment and
exercise prescription
not completed
□ Exercise prescription
communicated to the patient
and health care provider
□ Re-assessment
and exercise
prescription
completed
□ Re-assessment
and exercise
prescription not
completed
□ Revised exercise
prescription communicated to
the patient and health care
provider
se of
reventive
edications
Adherence to
prescribed preventive
medications
□ Patient has been
prescribed preventive
medications by his/
her health care
provider(s)
□ Individual education and
counseling about the
importance of adherence to
appropriate preventive
medications
□ Individual or
group education
completed
□ Patient is encouraged to
discuss questions or concerns
about prescribed preventive
medications with his/her
healthcare providers
or
□ Group education and
counseling about the
importance of adherence to
appropriate preventive
medications
arget goals are from the 2006 AHA/ACC Secondary Prevention Guidelines (39). Assessment terms and definitions are from the outcomes registry proposal.
BP  blood pressure; CABG  coronary artery bypass grafting; CHF  congestive heart failure; CR  cardiac rehabilitation/secondary prevention; CVD  cardiovascular disease; DM  diabetes
ellitus; HDL-C high-density lipoprotein cholesterol; IFG impaired fasting glucose; LDL-C low-density lipoprotein cholesterol; MImyocardial infarction; PCI percutaneous coronary intervention.
S
a
p
a
S
M
M
S
A
J
T
T
P
E
D
A
M
R
S
K
A
R
M
1413JACC Vol. 50, No. 14, 2007 Thomas et al.
October 2, 2007:1400–33 AACVPR/ACC/AHA Performance Measuresuch strategies should be part of an overall systems-based
pproach to minimize inappropriate gaps and variation in
atient care, optimize delivery of health-promoting services,
nd improve patient-centered health outcomes.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33PPENDIX A. CARDIAC REHABILITATION/SECONDARY PREVENTION PERFORMANCE MEASUREMENT SET A
Performance Measure A-1
A-1. Cardiac Rehabilitation Patient Referral From an Inpatient Setting
ll patients hospitalized with a primary diagnosis of an acute myocardial infarction (MI) or chronic stable angina (CSA), or who during hospitalization have
ndergone coronary artery bypass graft (CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation are to be
eferred to an early outpatient cardiac rehabilitation/secondary prevention (CR) program.
umerator Number of eligible patients with a qualifying event/diagnosis who have been referred to an outpatient CR program prior to hospital
discharge or have a documented medical or patient-centered reason why such a referral was not made
(Note: The program may include a traditional CR program based on face-to-face interactions and training sessions or may include other
options such as home-based approaches. If alternative CR approaches are used, they should be designed to meet appropriate safety
standards.
A referral is defined as an official communication between the health care provider and the patient to recommend and carry out a
referral order to an early outpatient CR program. This includes the provision of all necessary information to the patient that will
allow the patient to enroll in an early outpatient CR program. This also includes a communication between the health care
provider or health care system and the CR program that includes the patient’s referral information for the program. A hospital
discharge summary or office note may potentially be formatted to include the necessary patient information to communicate to
the CR program [the patient’s cardiovascular history, testing, and treatments, for instance]. All communications must maintain
appropriate confidentiality as outlined by the 1996 Health Insurance Portability and Accountability Act [HIPAA].)
Exclusion Criteria:
● Patient-oriented barriers (patient refusal, for example)
● Provider-oriented criteria (patient deemed to have a high-risk condition or a contraindication to exercise, for example)
● Health care system barriers (financial barriers or lack of CR programs near a patient’s home, for example)
enominator Number of hospitalized patients in the reporting period hospitalized with a qualifying event/diagnosis who do not meet any of the
exclusion criteria mentioned above
eriod of Assessment Inpatient hospitalization
ethod of Reporting Proportion of health care system’s patients with a qualifying event/diagnosis who had documentation of their referral to an outpatient
CR program
ources of Data Administrative data and/or medical records
Rationale
key component to outpatient CR program utilization is the appropriate and timely referral of patients. Generally, the most important time for this referral to take
lace is while the patient is hospitalized for a qualifying event/diagnosis (MI, CSA, CABG, PCI, cardiac valve surgery, or cardiac transplantation).
his performance measure has been developed to help health care systems implement effective steps in their systems of care that will optimize the appropriate
eferral of a patient to an outpatient CR program.
his measure is designed to serve as a stand-alone measure or, preferably, to be included within other performance measurement sets that involve disease states
r other conditions for which CR services have been found to be appropriate and beneficial (e.g., following MI, CABG surgery). This performance measure is provided
n a format that is meant to allow easy and flexible inclusion into such performance measurement sets.
ffective referral of appropriate inpatients to an outpatient CR program is the responsibility of the health care team within a health care system that is primarily
esponsible for providing cardiovascular care to the patient during the hospitalization.
Corresponding Guidelines and Clinical Recommendations
CC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery (21)
lass I (for the description of the class of recommendations and level of evidence used in this document, see Table 1)
ardiac rehabilitation should be offered to all eligible patients after CABG. (Level of Evidence: B)
CC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (40)
lass I
ardiac rehabilitation/secondary prevention programs, when available, are recommended for patients with ST-elevation myocardial infarction, particularly those with
ultiple modifiable risk factors and/or those with moderate- to high-risk patients in whom supervised exercise training is warranted. (Level of Evidence: C)
CC/AHA 2002 Guideline Update for the Management of Patients with Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction (41)
lass I
onsider the referral of patients who are smokers to a smoking cessation program or clinic and/or an outpatient CR program. (Level of Evidence: B)
CC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina (19)
lass I
omprehensive CR program (including exercise). (Level of Evidence: B)
CC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary (42)
lass I
xercise training is beneficial as an adjunctive approach to improve clinical status in ambulatory patients with current or prior symptoms of heart failure and
educed left ventricular ejection fraction (LVEF). (Level of Evidence: B)
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October 2, 2007:1400–33 AACVPR/ACC/AHA Performance Measuresvidence-Based Guidelines for Cardiovascular Disease Prevention in Women (22)
lass I
comprehensive risk-reduction regimen, such as cardiovascular or stroke rehabilitation or a physician-guided home- or community-based exercise training program,
hould be recommended to women with a recent acute coronary syndrome or coronary intervention, new-onset or chronic angina, recent cerebrovascular event,
eripheral arterial disease (Level of Evidence: A), or current/prior symptoms of heart failure and an LVEF 40%. (Level of Evidence: B)
Challenges to Implementation
dentification of all eligible patients in an inpatient setting will require that a timely, accurate, and effective system be in place. Communication of referral information by
he inpatient hospital service team to the outpatient CR program represents a potential challenge to the implementation of this performance measure. However, this task
s generally performed by an inpatient cardiovascular care team member, such as an inpatient CR team member or a hospital discharge planning team member.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33Performance Measure A-2
A-2. Cardiac Rehabilitation Patient Referral From an Outpatient Setting
ll patients evaluated in an outpatient setting who within the past 12 months have experienced an acute myocardial infarction (MI), coronary artery bypass graft
CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina (CSA) and have not
lready participated in an early outpatient cardiac rehabilitation/secondary prevention (CR) program for the qualifying event/diagnosis are to be referred to such a
rogram.
umerator Number of patients in an outpatient clinical practice who have had a qualifying event/diagnosis during the previous 12 months,
who have been referred to an outpatient CR program.
(Note: The program may include a traditional CR program based on face-to-face interactions and training sessions or other options that
include home-based approaches. If alternative CR approaches are used, they should be designed to meet appropriate safety standards.
A referral is defined as an official communication between the health care provider and the patient to recommend and carry out a referral
order to an outpatient CR program. This includes the provision of all necessary information to the patient that will allow the patient to
enroll in an outpatient CR program. This also includes a communication from the health care provider and/or health care system to the
CR program that includes necessary information for the patient’s referral information for the program. A hospital discharge summary or
office note may potentially be formatted to include the necessary patient information to communicate to the CR program [the patient’s
cardiovascular history, testing, and treatments, for instance]. All communications must maintain an appropriate level of confidentiality as
outlined by the 1996 Health Insurance Portability and Accountability Act [HIPAA].)
Exclusion Criteria:
● Patient-oriented barriers (patient refusal, for example)
● Provider-oriented criteria (patient deemed to have a high-risk condition or a contraindication to exercise, for example)
● Health care system barriers (financial barriers or lack of CR programs near a patient’s home, for example)
enominator Number of patients in an outpatient clinical practice who have had a qualifying event/diagnosis during the previous 12 months and
who do not meet any of the exclusion criteria mentioned in the Numerator section above
eriod of Assessment Twelve months following a qualifying event/diagnosis
ethod of Reporting Proportion of patients in an outpatient practice who have had a qualifying event/diagnosis during the past 12 months and have
been referred to a CR program
ources of Data Administrative data and/or medical records
Rationale
ardiac rehabilitation services have been shown to help reduce morbidity and mortality in persons who have experienced a recent coronary artery disease event, but
hese services are used in less than 30% of eligible patients (26). A key component to CR utilization is the appropriate and timely referral of patients to an
utpatient CR program. While referral takes place generally while the patient is hospitalized for a qualifying event (MI, CSA, CABG, PCI, cardiac valve surgery, or
eart transplantation), there are many instances in which a patient can and should be referred from an outpatient clinical practice setting (e.g., when a patient does
ot receive such a referral while in the hospital, or when the patient fails to follow through with the referral for whatever reason).
his performance measure has been developed to help health care systems implement effective steps in their systems of care that will optimize the appropriate
eferral of a patient to an outpatient CR program.
his measure is designed to serve as a stand-alone measure or, preferably, to be included within other performance measurement sets that involve disease states
r other conditions for which CR services have been found to be appropriate and beneficial (e.g., following MI, CABG surgery). This performance measure is provided
n a format that is meant to allow easy and flexible inclusion into such performance measurement sets.
eferral of appropriate outpatients to a CR program is the responsibility of the health care provider within a health care system that is providing the primary
ardiovascular care to the patient in the outpatient setting.
Corresponding Guidelines and Clinical Recommendations
ee Clinical Recommendations section from Performance Measure A-1 above.
Challenges to Implementation
dentification of all eligible patients in an outpatient clinical practice will require that a timely, accurate, and effective system be in place. Communication of referral
nformation by the outpatient clinical practice team to the outpatient CR program represents a potential challenge to the implementation of this performance
easure.
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Performance Measure B-1
B-1. Structure-Based Measurement Set
he cardiac rehabilitation/secondary prevention (CR) program has policies in place to demonstrate that:
. A physician-director is responsible for the oversight of CR program policies and procedures and ensures that policies and procedures are consistent with evidence-
based guidelines, safety standards, and regulatory standards (43). This includes appropriate policies and procedures for the provision of alternative CR program
services, such as home-based CR.
. An emergency response team is immediately available to respond to medical emergencies (44).
A. In a hospital setting, physician supervision is presumed to be met when services are performed on hospital premises (45).
B. In the setting of a free-standing outpatient CR program (owned/operated by a hospital, but not located on the main campus), a physician-directed emergency
response team must be present and immediately available to respond to emergencies.
C. In the setting of a physician-directed clinic or practice, a physician-directed emergency response team must be present and immediately available to respond
to emergencies.
. All professional staff have successfully completed the National Cognitive and Skills examination in accordance with the AHA curriculum for basic life support
(BLS) with at least one staff member present who has completed the National Cognitive and Skills examination in accordance with the AHA curriculum for
advanced cardiac life support (ACLS) and has met state and hospital or facility medico-legal requirements for defibrillation and other related practices (43,46,47).
. Functional emergency resuscitation equipment and supplies for handling cardiovascular emergencies are immediately available in the exercise area (44).
umerator The number of CR programs in the health care system that meet these structure-based performance measure criteria
enominator All CR programs within a health care system
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Written program policies
Rationale
he delivery of CR services is physician-directed and provided by a multidisciplinary staff of health care professionals. A system for communication between a
hysician-director with expertise in CVD management and a referring or primary physician enhances the program’s success in helping that patient achieve
ndividualized target goals. It is the responsibility of the physician-director to assure that the information and instruction given to patients in CR is consistent with the
ost current clinical practice guidelines.
here is a growing trend among patients referred to and completing early outpatient CR to be older, at higher risk, and have more chronic comorbidities (48).
edical supervision is the most important day-to-day safety factor in CR (43). Personnel and equipment for ACLS are essential to the adequate delivery of
mergency care for patients who experience cardiac arrest or other life-threatening events during CR sessions.
lthough rare, cardiovascular emergencies can occur during exercise training in CR programs. Studies suggest that the incidence of cardiac arrest requiring
efibrillation is approximately 1 arrest every 100,000 patient-hours (49). Practice guidelines for management of cardiac arrest include the use of BLS and ACLS
trategies, such as early defibrillation (17,43). Such strategies have been shown to help improve outcomes in persons who experience cardiac arrest (50).
ome CR programs seek certification of their program by health care organizations, such as AACVPR, in order to show that they meet certain standards for the
elivery of CR services. Such a certification process, while outside the scope of this document, may result in documentation of a program’s ability to meet this (B-1)
nd other CR performance measures mentioned in this document. Currently, for instance, CR program certification through AACVPR requires that all of the above
olicies (Items 1 to 4 above) are in place and operational.
Corresponding Guidelines and Clinical Recommendations
edical Director Responsibilities for Outpatient Cardiac Rehabilitation/Secondary Prevention Programs (43)
No class of recommendation or level of evidence given)
here is a physician-director responsible for program oversight and to ensure that policies and procedures are consistent with evidence-based guidelines, safety
tandards, and regulatory standards.
ACVPR Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs (51)
No class of recommendation or level of evidence given)
ll professional staff have completed BLS training; at least 1 staff member is present who has successfully completed training in ACLS.
edical supervision for moderate- to high-risk patients will be provided by a physician, registered nurse, or other appropriately trained staff member who has
uccessfully completed AHA curriculum for ACLS and has met state and hospital or facility medico-legal requirements for defibrillation and other related practices.
xercise Standards for Testing and Training: A Statement for Health Professionals From the American Heart Association. AHA Scientific Statement (52)
No class of recommendation or level of evidence given)
n emergency response team is immediately available to respond to medical emergencies.
MS National Coverage Determination for Cardiac Rehabilitation Programs (45)
No class of recommendation or level of evidence given)
unctional emergency resuscitation equipment and supplies for handling cardiovascular emergencies are immediately available in the exercise area.
Challenges to Implementation
dherence to this measure requires the engagement of a physician-director who is accountable for policy development and implementation.
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B-2. Assessment of Risk for Adverse Cardiovascular Events
he cardiac rehabilitation/secondary prevention (CR) program has the following processes in place:
. Documentation, at program entry, that each patient undergoes an assessment of clinical status (e.g., symptoms, medical history) in order to identify high-risk
conditions for adverse cardiovascular events.
. A policy to provide recurrent assessments for each patient during the time of participation in the CR program in order to identify any changes in clinical status
that increase the patient’s risk of adverse cardiovascular events. If such findings are noted, the CR staff contacts the program’s physician director and/or the
patient’s primary health care provider according to thresholds for communication included in the policies developed for Performance Measure B-3j.
umerator Number of CR programs in the health care system that meet the performance measure for assessment of risk for adverse cardiovascular events
enominator Number of CR programs in the health care system
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Written program policies
Rationale
A standardized assessment should be performed to identify patients with unstable symptoms and other factors that place the patient at increased risk for adverse
cardiovascular events (17).
When high-risk findings are noted, a patient should be considered for prompt evaluation and treatment, and rehabilitation recommendations should be adjusted
accordingly.
Recurrent adverse cardiovascular events are relatively common in persons with cardiovascular disease (CVD). In 1 study from Olmsted County, Minnesota, nearly
half of patients discharged from the hospital following a myocardial infarction (MI) had a recurrent adverse cardiovascular event in the 3 years following their MI
(53).
However, adverse events are rare during CR early after a CVD event, occurring approximately once in every 100,000 patient-hours (49). This safety record is likely
due in part to standard procedures that exist in CR programs to frequently screen patients for signs and symptoms that increase their risk for adverse
cardiovascular events (17,50). If a CR participant develops abnormal cardiovascular signs (significant arrhythmias or blood pressure abnormalities, for example) or
symptoms (exertional chest pain, for instance) they typically receive prompt evaluation and care.
Published reports suggest limited accuracy of the risk stratification methods from the AACVPR, ACC/AHA, and the American College of Physicians in identifying
patients at risk for adverse events during CR sessions (54). However, 1 study found that a combination of the AACVPR criteria with a comorbidity index helped
improve the accuracy of risk stratification, particularly among female patients (55). A significant limitation to these studies is the fact that patients identified at high
risk undergo additional evaluation and treatment to lower their risk, thereby dampening the ability of such screening measures to accurately identify individuals at
increased risk of adverse cardiovascular events.
This performance measure does not cover the assessment of modifiable risk factors, such as blood pressure, cholesterol, and diabetes. Assessment of modifiable
risk factors related to CVD progression and recurrent CVD events is covered in Performance Measure B-3.
Corresponding Guidelines and Clinical Recommendations
AACVPR Guidelines for Cardiac Rehabilitation and Secondary Prevention Programs (51)
(No class of recommendation or level of evidence given)
All cardiac patients entering exercise rehabilitation should be stratified according to the risk for the occurrence of cardiac events during exercise.
Exercise Standards for Testing and Training: A Statement for Health Care Professionals From the American Heart Association (52)
(No class of recommendation or level of evidence given)
Screening procedures can be used that identify an individual who is at risk for an exercise-related cardiac event, which may be helpful in reducing these
occurrences.
After the medical evaluation is complete, subjects can be classified by risk on the basis of their characteristics. This classification is used to determine the need for
subsequent supervision and the level of monitoring required.
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B-3. Individualized Assessment and Evaluation of Modifiable Cardiovascular Risk Factors, Development of Individualized Interventions,
and Communication With Other Health Care Providers
his performance measure includes 10 individual sub-measures for the evaluation of modifiable cardiovascular risk factors, development of individualized
nterventions, and communication with other health care providers concerning these risk factors and interventions.
he rationale for including both recognition and intervention for satisfactory fulfillment of these measures is predicated upon the belief that high-quality
ardiovascular care requires both the identification and treatment of known cardiovascular risk factors.
n important component of this performance measure is the expectation that the cardiac rehabilitation/secondary prevention (CR) staff communicates with
ppropriate primary care providers and treating physicians in order to help coordinate risk factor management and to promote life-long adherence to lifestyle and
harmacological therapies. (See Performance Measure B-3j for more specific coverage of communication with the patient’s primary health care provider.)
Performance Measure B-3a—Individualized Assessment of Tobacco Use
or each eligible patient enrolled in the CR program, there is documentation that the following criteria have been met:
. An assessment is made of current and past tobacco use.
. If current tobacco use is identified, an intervention plan is recommended to the patient and communicated to the primary care provider and/or cardiologist. This
plan may include individual education, counseling, and/or referral to a tobacco cessation program.
. Prior to completion of the CR program, the patient’s tobacco use status and tobacco avoidance treatment plan are reassessed and communicated to the patient
as well as to the primary care provider and/or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for tobacco use
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
essation of tobacco use is most successful when health care providers work together with patients to identify and implement effective treatment strategies.
ersons with CVD who stop smoking reduce their cardiovascular risk by approximately 35% (56,57).
Corresponding Guidelines and Clinical Recommendations
HA/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
oal: Complete cessation. (Level of Evidence: B)
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
oals:
hort-term: Patient will demonstrate readiness to change by initially expressing decision to quit and selecting a quit date. Subsequently, patient will quit smoking
nd all tobacco use, and adhere to pharmacological therapy (if prescribed), and practice relapse prevention strategies; patient will resume cessation plan as quickly
s possible when temporary relapse occurs.
ong-term: Complete abstinence from smoking and use of all tobacco products for at least 12 months (maintenance) from quit date.
HA Scientific Statement: Diet and Lifestyle Recommendations Revision 2006 (58)
No class of recommendation or level of evidence given)
oal: Avoid use of (and exposure to) tobacco products.
Related Performance Measurement Sets
linical Performance Measures: Chronic Stable Coronary Artery Disease. Tools Developed by Physicians for Physicians. Physician Consortium for Performance
mprovement (59)
ercentage of patients queried 1 or more times during the reporting year about cigarette smoking.
ercentage of patients identified as cigarette smokers who received smoking cessation intervention during the reporting year.
Challenges to Implementation
his measure relies on patient self-report.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33Performance Measure B-3b—Individualized Assessment of Blood Pressure (BP) Control
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. An assessment is made of BP control, with target goals defined by the AHA/ACC secondary prevention guidelines.
. For patients with a diagnosis of hypertension, an intervention plan is developed. This should include education about target BP goals, medication compliance,
lifestyle modification for optimal dietary and physical activity habits, and weight control.
. During the CR program, BP control is reassessed and communicated to the patient as well as to the primary care provider and/or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for BP control
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
he BP levels represent a strong, consistent, continuous, independent, and etiologically relevant risk factor for cardiovascular and renal disease. Optimal control of
P has a beneficial impact on lowering cardiovascular risk (39,57).
Corresponding Guidelines and Clinical Recommendations
HA/ACC Guidelines for Secondary Prevention for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
oal: 140/90 mm Hg or 130/80 mm Hg if patient has diabetes or chronic kidney disease. (Level of Evidence: B, for lifestyle modification; A, for
harmacological treatment)
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (58)
No class of recommendation or level of evidence given)
oal: Continued assessment and modification of intervention until normalization of BP.
HA Scientific Statement: Diet and Lifestyle Recommendations Revision 2006 (58)
No class of recommendation or level of evidence given)
oal: Aim for a normal BP.
eventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure
ducation Program (60)
No class of recommendation or level of evidence given)
reating systolic BP and diastolic BP to targets that are less than 140/90 mm Hg is associated with a decrease in CVD complications. In patients with hypertension
ith diabetes or renal disease, the BP goal is less than 130/80 mm Hg.
Related Performance Measurement Sets
linical Performance Measures: Chronic Stable Coronary Artery Disease. Tools Developed by Physicians for Physicians. Physician Consortium for Performance
mprovement (58)
ercentage of patients who had a BP measurement during the last office visit.
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October 2, 2007:1400–33 AACVPR/ACC/AHA Performance MeasuresPerformance Measure B-3c—Individualized Assessment of Optimal Lipid Control
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. An assessment of blood lipid control and use of lipid-lowering medications, with target goals defined by the AHA/ACC secondary prevention guidelines.
. For patients with a diagnosis of hyperlipidemia, an intervention plan has been recommended to the patient. This should include education about target lipid
goals, importance of medication compliance, lifestyle modification for optimal dietary and regular physical activity habits, and weight control.
. Prior to completion of the CR program, lipid control and the lipid management plan, including lifestyle modification, are reassessed and communicated to the
patient as well as to the primary care provider and/or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for lipid control
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
ultiple clinical trials have shown the benefit of lipid-lowering agents and lifestyle modification for patients with documented cardiovascular disease (39). A more
ggressive low-density lipoprotein (LDL) target goal of 70 mg/dL should be considered for persons with multiple cardiovascular risk factors, particularly when they
re under suboptimal control (e.g., a patient with coronary artery disease who continues to smoke).
Corresponding Guidelines and Clinical Recommendations
HA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
oal: Low-density lipoprotein-cholesterol (LDL-C) 100 mg/dL; If triglycerides are 200 mg/dL, non–high-density lipoprotein cholesterol (HDL-C) should be 130
g/dL. (Level of Evidence: B, for lifestyle modification; A, for pharmacological treatment)
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
oals:
hort-term: Continued assessment and modification of intervention until LDL 100 mg/dL (further reduction to a goal 70 mg/dL is considered reasonable).
ong-term: LDL 100 mg/dL (further reduction to a goal 70 mg/dL is considered reasonable). Secondary goal: non–HDL-C 130 mg/dL (further reduction to a
oal of 100 mg/dL is considered reasonable).
HA Scientific Statement: Diet and Lifestyle Recommendations Revision 2006 (58)
No class of recommendation or level of evidence given)
oal: Aim for recommended levels of LDL-C, HDL-C, and triglycerides.
Related Performance Measurement Sets
linical Performance Measures. Chronic Stable Coronary Artery Disease. Tools Developed by Physicians for Physicians. Physician Consortium for Performance
mprovement (59)
ercentage of patients receiving at least one lipid profile during the reporting year. Percentage of patients who are receiving a statin (based on current ACC/AHA
uidelines).
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33Performance Measure B-3d—Individualized Assessment of Physical Activity Habits
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. An assessment of current physical activity habits.
. If physical activity habits at time of program entry do not meet suggested guidelines as defined by the AHA/ACC secondary prevention guidelines, then
recommendations to improve physical activity habits are given to the patient.
. Prior to completion of the CR program, physical activity habits and the physical activity intervention plan are reassessed and communicated to the patient as well
as to the primary care provider and/or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for physical activity habits
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting A standardized method for assessing physical activity is to be used, with results entered into an inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
dherence to regular physical activity has been associated with a 20% to 30% reduction in all-causes mortality in cardiovascular disease (CVD) patients (9).
Corresponding Guidelines and Clinical Recommendations
HA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
oal: 30 min, 7 d per week (minimum 5 d per week). (Level of Evidence: B)
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (56)
No class of recommendation or level of evidence given)
oal: 30 to 60 min per d of moderate-intensity physical activity on 5 or more (preferably most) days of the week.
xercise and Physical Activity in the Prevention and Treatment of Atherosclerotic Cardiovascular Disease: A Statement From the Council on Clinical Cardiology
Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) (61)
No class of recommendation or level of evidence given)
ealth professionals should prescribe physical activity programs commensurate with those recommended by the Centers for Disease Control and Prevention and the
merican College of Sports Medicine, that is, 30 min or more of moderate-intensity physical activity such as brisk walking on most, and preferably all, days of the
eek.
Challenges to Implementation
ommunity-based exercise may not utilize modalities designed for elderly patients and those with neurological and musculoskeletal disease, making continued
egular physical activity a challenge for some patients.
F1
2
3
N
D
P
M
S
O
p
A
C
G
A
(
G
S
w
L
A
(
G
(
G
h
t
f
w
W
1425JACC Vol. 50, No. 14, 2007 Thomas et al.
October 2, 2007:1400–33 AACVPR/ACC/AHA Performance MeasuresPerformance Measure B-3e—Individualized Assessment of Weight Management
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. An assessment of body weight/composition, including the measurement of either body mass index (BMI) or waist circumference with targets as defined by the
AHA/ACC secondary prevention guidelines (39).
. If the body weight/composition measure(s) is (are) above recommended goal(s), then an intervention plan is recommended to the patient. This should include
education about target goals and lifestyle modification including a healthy diet, behavior change, and regular physical activity and/or referral to a weight
management program.
. Prior to completion of the CR program, body weight/composition and the intervention plan are reassessed and communicated to the patient as well as the
primary care provider and/or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for assessment of weight management
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
besity is an independent risk factor for cardiovascular disease (CVD) and adversely affects CVD risk factors. By adhering to diet and lifestyle recommendations,
atients can substantially reduce their risk of cardiovascular disease (58).
Corresponding Guidelines and Clinical Recommendations
HA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
oal: BMI, 18.5 to 24.9 kg/m2; waist circumference, men 40 inches, women 35 inches. (Level of Evidence: B)
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
oals:
hort-term: Continued assessment and modification of interventions until progressive weight loss is achieved. Provide referral to specialized, validated nutrition
eight loss programs if weight goals are not achieved.
ong-term: Adherence to diet and physical activity/exercise program aimed toward attainment of established weight goal.
HA Scientific Statement: Diet and Lifestyle Recommendations: Revision 2006 (58)
No class of recommendation or level of evidence given)
oal: Aim for a healthy body weight.
No class of recommendation or level of evidence given)
oals: Balance caloric intake and physical activity to achieve and maintain a healthy body weight; consume a diet rich in vegetables and fruits; choose whole-grain,
igh-fiber foods; consume fish, especially oily fish, at least twice a week; limit intake of saturated fat to 7% of energy, trans fat to 1% of energy, and cholesterol
o 300 mg/day by choosing lean meats and vegetable alternatives, fat-free (skim) or low-fat (1% fat) dairy products and minimize intake of partially hydrogenated
ats; minimize intake of beverages and foods with added sugars; choose and prepare foods with little or no salt; if you consume alcohol, do so in moderation; and
hen you eat food prepared outside of the home, follow these diet and lifestyle recommendations.
Challenges to Implementation
eight management relies on patient compliance with diet and lifestyle recommendations.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33Performance Measure B-3f—Individualized Assessment of the Diagnosis of Diabetes Mellitus (DM) or Impaired Fasting Glucose (IFG)
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. Assessment of the diagnosis of IFG and DM, with definitions as described in the most recent American Diabetes Association Standards of Medical Care in
Diabetes Position Statement (62).
. If the patient has a diagnosis of IFG or DM, then an intervention plan is recommended to the patient for glycemic monitoring during exercise, for glycemic goals,
and for recommendations concerning medical nutrition therapy and/or skill training sessions (if not previously attended).
. Prior to completion of the CR program, DM/IFG status, and the DM/IFG intervention plan are reassessed and communicated to the patient as well as to the
primary care provider and/or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for DM/IFG
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
he presence of DM or IFG has been linked to unfavorable long-term cardiovascular outcomes. Because improved glycemic control has been shown to favorably
ffect cardiovascular morbidity and mortality (61), the CR program setting is an ideal environment to educate patients about the implications of DM or IFG and to
nitiate the behavior patterns that foster improved glycemic control (56).
Corresponding Guidelines and Clinical Recommendations
hysical Activity/Exercise and Type 2 Diabetes: A Consensus Statement from the American Diabetes Association (63)
No class of recommendation given)
hose who take insulin or secretagogues should check capillary blood glucose before, after, and several hours after completing a session of physical activity, at
east until they know their usual glycemic responses to such activity. (Level of Evidence: E, from the American Diabetes Association (ADA) classification system, in
hich Level of Evidence: E is based on expert consensus or clinical experience)
merican Diabetes Association Standards of Medical Care in Diabetes-2006 (62)
No class of recommendation given)
owering HbA1C has been associated with a reduction of microvascular and neuropathic complications of diabetes. (Level of Evidence: A, from the ADA classification
ystem, in which Level A is based on clear evidence from well-conducted, generalizable, randomized controlled trials that are adequately powered.)
eople with DM should receive individualized medical nutrition therapy (MNT) as needed to achieve treatment goals, preferably provided by a registered dietitian
amiliar with the components of diabetes MNT. (Level of Evidence: B, from the ADA classification system, in which Level B is based on supportive evidence from
ell-conducted cohort studies.)
eople with DM should receive DM self-management education according to national standards when their DM is diagnosed and as needed thereafter. (Level of
vidence: B, see above)
HA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
nitiate lifestyle and pharmacotherapy to achieve near-normal HbA1C. (Level of Evidence: B) Begin vigorous modification of other risk factors. (Level of Evidence: B)
oordinate diabetic care with patient’s primary care physician or endocrinologist. (Level of Evidence: C)
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
ducate patient and staff to be alert for signs/symptoms of hypoglycemia or hyperglycemia and provide appropriate assessment and interventions.
each and practice self-monitoring skills for use during unsupervised exercise. Refer to registered dietitian for MNT. Consider referral to certified diabetic educator
or skill training, medication instruction, and support groups.
Challenges to Implementation
atients may not be aware that they have IFG or DM. In addition, it may be difficult for CR staff to obtain medical records to verify or refute the diagnosis. Given the
atter, either patient self-report or medical records, if available, may be used to meet these criteria.
F1
2
3
N
D
P
M
S
D
a
a
r
D
(
T
a
c
r
D
1427JACC Vol. 50, No. 14, 2007 Thomas et al.
October 2, 2007:1400–33 AACVPR/ACC/AHA Performance MeasuresPerformance Measure B-3g—Individualized Assessment of the Presence or Absence of Depression
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. Assessment of the presence or absence of depression, using a valid and reliable screening tool.
. If clinical depression is suspected as a result of screening, this has been discussed with the patient.
. If clinical depression is suspected as a result of screening, the primary care provider and/or mental health care provider have been notified.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for depression
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
epression is highly prevalent among patients following acute cardiac events, with 20% to 45% of patients suffering significant levels of depressive symptoms after
n acute myocardial infarction (MI) (64,65). Depression has been shown to be a powerful, independent risk factor for cardiac mortality after an acute MI or unstable
ngina (66,67). Several studies suggest that depressed patients with CVD benefit from CR programs by improving coping skills and self-image, reducing biological
isk factors such as social isolation and smoking, providing emotional support, and improving quality of life scores (68).
Corresponding Guidelines and Clinical Recommendations
epression Screening in Cardiac Rehabilitation: AACVPR Task Force Report (69)
No class of recommendation or level of evidence given)
he AACVPR recommends that appropriately trained health care professionals in the CR setting assess for depression using a valid and reliable screening tool and
sk specific questions about depression as a part of the intake assessment and/or clinical interview. They also recommend that cardiac rehabilitation professionals
ommunicate findings indicating possible clinical depression to referring physicians, facilitate referral of patients for appropriate treatment, and periodically
eassess therapeutic progress.
Challenges to Implementation
epression screening includes patient self-report, but validated self-report tools are available to help facilitate screening for depression.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33Performance Measure B-3h—Individualized Assessment of Exercise Capacity
or each eligible patient enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the following criteria have been met:
. Assessment of maximal or submaximal exercise capacity, using at least 1 of several possible assessment methods that has standard end points as defined by
groups such as the American College of Sports Medicine and ACC/AHA practice guidelines and scientific statements (52,70)
. An individualized exercise prescription, based on the assessment of exercise capacity, is recommended to the patient and communicated to the primary care
provider and/or cardiologist.
. Prior to completion of the CR program, change in exercise capacity is re-assessed and communicated to the patient as well as to the primary care provider and/
or cardiologist.
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for assessment of exercise capacity
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
eta-analyses and systematic reviews have concluded that comprehensive, exercise-based CR reduces mortality rates in patients with cardiovascular disease (CVD)
2,3,5–7,9–11).
Corresponding Guidelines and Clinical Recommendations
CC/AHA 2002 Guidelines Update for Exercise Testing: Summary Article (71)
lass I
ssessment of symptom-limited exercise tolerance for activity prescription.
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
evelop a documented individualized exercise prescription for aerobic and resistance training that is based on evaluation findings, risk stratification, patient and
rogram goals, and resources. Exercise prescription should specify frequency, intensity, duration, and modalities.
orking Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology Position Paper (15)
No class of recommendation or level of evidence given)
oderate- to high-risk cardiac patients must undergo an individualized exercise program and receive an exercise prescription within the limits imposed by their
isease.
Challenges to Implementation
n some cases, results of recent stress tests are available to assess exercise capacity, but this is not universal. The CR program may use an alternative assessment
f exercise capacity, such as submaximal treadmill testing or a 6-min walk.
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October 2, 2007:1400–33 AACVPR/ACC/AHA Performance MeasuresPerformance Measure B-3i—Individualized Adherence to Preventive Medications
or each eligible patient with coronary artery disease enrolled in the cardiac rehabilitation/secondary prevention (CR) program, there is documentation that the
ollowing criterion has been met:
. The patient has received individual or group education concerning the importance of adherence to preventive medications that are described in the AHA/ACC
secondary prevention guidelines. (Note: Patients should be encouraged to discuss questions or concerns about prescribed preventive medications with their
health care providers.)
umerator Number of patients in the health care system’s CR program(s) who meet the performance measure for adherence to preventive medications
enominator Number of patients in the health care system’s CR program(s)
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Electronic- or paper-based prospective flow sheet (preferred) or retrospective medical record review
Rationale
he use of preventive medications that may or may not be tied to a specific risk factor (aspirin, omega-3 fatty acids, beta blockers, and angiotensin-converting
nzyme inhibitors (ACEI)/angiotensin-receptor blockers (ARB) agents, for instance) are also critically important in reducing recurrent cardiovascular events in
atients enrolled in a CR program. A gap in their usage is common, but can be corrected with the help of systematic programs, such as CR programs, that can
romote the appropriate use of preventive medications and thereby improve patient outcomes (26).
Corresponding Guidelines and Clinical Recommendations
HA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (39)
lass I
se of antiplatelet agents, renin-angiotensin-aldosterone system blockers, and beta blockers. (Level of Evidence: B)
Related Performance Measurement Sets
linical Performance Measures: Chronic Stable Coronary Artery Disease. Tools Developed by Physicians for Physicians. Physician Consortium for Performance
mprovement (59)
ercentage of patients receiving: antiplatelet therapy, drug therapy for lowering cholesterol, or beta-blocker therapy post-myocardial infarction.
CC/AHA STEMI/NSTEMI Clinical Performance Measures (72)
cute myocardial infarction patients without contraindications who are prescribed the following drug at discharge: 1) aspirin, 2) beta blocker, 3) lipid-lowering
herapy, or 4) ACEI or ARB for left ventricular systolic dysfunction.
Challenges to Implementation
ehabilitation teams need to understand how current clinical practice guidelines relate to individual patients in order to optimize education.
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AACVPR/ACC/AHA Performance Measures October 2, 2007:1400–33Performance Measure B-3j—Communication With Health Care Providers
here is a policy in place to ensure communication with health care providers, including individual patient status related to each modifiable risk factor at entrance
o and completion of the cardiac rehabilitation/secondary prevention (CR) program, as well as when thresholds are met for more frequent or urgent communication
oncerning suboptimal risk factor control.
umerator The number of CR programs in the health care system that meet the performance measure for communication with health care providers
enominator The number of CR programs in the health care system
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Written program policies
Rationale
ptimal communication between the CR team and appropriate health care providers will promote timely adjustments in a patient’s medical regimen, leading to
mproved risk factor modification.
Corresponding Guidelines and Clinical Recommendations
HA/AACVPR Scientific Statement: Core Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
t is essential to the success of any program that each of these interventions is performed in concert with the patient’s primary care provider and/or cardiologist,
ho will subsequently supervise and refine these interventions over the long term.
edical Director Responsibilities for Outpatient Cardiac Rehabilitation/Secondary Prevention Programs (43)
No class of recommendation or level of evidence given)
y working closely with referring physicians, the cardiac rehabilitation team can assist the patient in reaching target goals more effectively.
Challenges to Implementation
R programs may not have access to all data related to risk factor control, such as most recent lipid profile, HbA1C, or patient-specific contraindications to
reventive medications.
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October 2, 2007:1400–33 AACVPR/ACC/AHA Performance MeasuresPerformance Measure B-4
B-4. Monitor Response to Therapy and Document Program Effectiveness
or each cardiac rehabilitation/secondary prevention (CR) program in a health care system, a written policy is in place to:
. Document the percentage of patients for whom the CR program has received a formal referral request who actually enroll in the program.
. Document for each patient a standardized plan to assess completion of the prescribed course of CR as defined on entrance to the program.
. Document for each patient a standardized plan to assess outcome measurements at the initiation and again at the completion of CR, including at least 1
outcome measure for the core program components as outlined in the Cardiac Rehabilitation/Secondary Prevention Performance Measure Set B, Performance
Measure 3.
. Describe the program’s methodology to document program effectiveness and initiate quality improvement strategies.
umerator Number of CR programs in the health system that meet this performance measure for monitoring response to therapy and documenting
program effectiveness
enominator Number of CR programs in the health care system
eriod of Assessment Per reporting year
ethod of Reporting Inclusive data collection tracking sheet
ources of Data Written program policies
Rationale
ontinuous quality improvement relies on collecting information about individual response to therapy as well as analysis of aggregate data to assess program
ffectiveness. The recommendation is that each CR program provides evidence of a standardized method to document individual patient outcomes on completion
f the course of CR as defined on intake to the CR program which, in aggregate, will permit documentation of program effectiveness and quality improvement
nitiative success.
utcome assessment and evaluation provides evidence of effectiveness of therapeutic interventions. According to a recent report of the National Heart, Lung, and
lood Institute, this enhances the migration of best practice to clinical practice, improves decision making and the quality of care provided, and supports the
ptimal allocation of health care resources for all patients (73).
he 2004 AACVPR Consensus Statement document suggests that “no single form [or] assessment protocol . . . will fit the needs of all programs (74). The
ocument gives examples of outcome measures for evaluating program effectiveness and communicating with other health care professionals, providing the basis
or a flexible “structural framework . . . that will guide programs in the development of standardized assessment protocols that fit their specific needs” (74).
nitiation and completion of the prescribed course of CR, as defined on admission assessment, are keys to promoting both life-long behavior change as well as
hysiologic adaptations from regular exercise. Comprehensive CR programs include core components designed to address secondary prevention issues which can
mprove with patient self-management. Reassessment of outcome measures after completion of CR can help programs assess their performance in each of these
ore components. It is anticipated that programs would assess different core components outcomes over time, using aggregate results to assess issues such as
verall program performance, alternative approaches to programming, and programming in underserved populations such as minorities, women, and the elderly.
Corresponding Guidelines and Clinical Recommendations
ACVPR Consensus Statement. Outcomes Evaluation in Cardiac Rehabilitation/Secondary Prevention Programs: Improving Patient Care and Program Effectiveness
74)
No class of recommendation or level of evidence given)
ardiac rehabilitation programs need to establish a standardized method of data collection and maintain effective communication with other health care providers
ho also provide care for the referred patient.
ore Components of Cardiac Rehabilitation/Secondary Prevention Programs: 2007 Update (57)
No class of recommendation or level of evidence given)
he assessment and evaluation of at least 1 of the expected outcome measures is recommended for each of the core cardiac rehabilitation components.
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ame of Measure:
linical Rationale:
umerator:
enominator:
easure:
ate this measure on the following criteria. Disagree Moderate Agreement Agree
1 2 3 4 5
seful in Improving Patient Outcomes
. Evidence-based: The scientific basis of the measure is well established. 1 2 3 4 5
. Interpretable: The results of the measure are interpretable by
practitioners.
1 2 3 4 5
. Actionable: The measure addresses an area that is under the
practitioner’s control.
1 2 3 4 5
easure Design
. Denominator: The patient group to whom this measure applies
(denominator) is clinically meaningful.
1 2 3 4 5
. Numerator: The definition of conformance for this measure is clinically
meaningful.
1 2 3 4 5
. Validity:
a. The measure appears to measure what it is intended to (face validity). 1 2 3 4 5
b. The measure captures most meaningful aspects of care (content
validity).
1 2 3 4 5
c. The measure correlates well with other measures of the same aspect of
care (construct validity).
1 2 3 4 5
. Reliability: The measure is likely to be reproducible across organizations
and delivery settings.
1 2 3 4 5
easure Implementation
. Feasibility:
a. The data required for the measure are likely to be obtained with
reasonable effort.
1 2 3 4 5
b. The data required for the measure are likely to be obtained at
reasonable cost.
1 2 3 4 5
c. The data required for the measure are likely to be obtained within the
period allowed for data collection.
1 2 3 4 5
verall Assessment
Do Not Include Could Include Must Include
onsidering your assessment of this measure on all dimensions above, rate
his measure overall for inclusion into the performance measurement set.
1 2 3 4 5
Rating Form Guide
Attribute of Performance Considerations
seful in Improving Patient Outcomes
. Evidence-based: The scientific basis of the measure is well
established.
This can be confirmed by explicit reference to a published clinical practice guideline.
. Interpretable: The results of the measure are interpretable
by practitioners.
This is your assessment of the degree with which a provider can clearly understand what the
results mean and can take action if necessary.
. Actionable: The measure addresses an area that is under
the practitioner’s control.
This is your assessment of the degree with which a provider is empowered and can
influence the activities of the health care system toward improvement.
easure Design
. Denominator: The patient group to whom this measure
applies (denominator) is clinically meaningful.
Depending upon intended use of the measure, the data source, any inclusion or exclusion
criteria, and sampling frames are explicit. The criteria used must be clinically meaningful. An
algorithm for determining the denominator may be present.
. Numerator: The definition of conformance for this measure
is clinically meaningful.
The numerator may be specified using either explicit or implicit criteria. The criteria used
must be clinically meaningful. An algorithm for determining the numerator may be present.
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Attribute of Performance Considerations
. Validity:
a. The measure appears to measure what it is intended to
(face validity).
b. The measure captures most meaningful aspects of care
(content validity).
c. The measure correlates well with other measures of the
same aspect of care (construct validity).
This can be confirmed by your judgment of the clarity and comprehensiveness of the
measure. For those measures that have been actually tested for validity, you may see
indications of specific testing such as comparisons with the results of other methods,
criterion or gold standard validity testing, and criterion validity testing. There may also be
documentation that the health care construct underlying the measure is associated with
important health care processes/outcomes.
. Reliability: The measure is likely to be reproducible across
organizations and delivery settings.
This can be confirmed by specific tests undertaken by the measure developers. For those
measures that have been actually tested for reliability, you may see indications of types of
reliability testing such as test–retest reliability, inter-rater reliability, data accuracy checks,
and internal consistency analyses. If the measure has not been used in practice, indicate the
degree of likelihood that it is reproducible.
easure Implementation
. Feasibility:
a. The data required for the measure are likely to be
obtained with reasonable effort.
b. The data required for the measure are likely to be
obtained at reasonable cost.
c. The data required for the measure are likely to be
obtained within the period allowed for data collection.
From your perspective, the required data can be typically abstracted from patient charts, or
there are national registries and databases readily available. For those measures actually
being used, there is information on the data collection approach and the system required to
support the measure.
verall Assessment
onsidering your assessment of this measure on all dimensions
bove, rate this measure for overall inclusion in the
erformance measurement set.
Consider a balance in the continuum of care. Consider overall purpose of the measurement
set and the intended user.
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